Full-Time

Senior Supplier Manufacturing Engineer

Machining

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

Hybrid

Hybrid role; on-site in Sunnyvale, California required.

Bachelor's, Master's, PhD

Category
Mechanical Engineering (1)
Required Skills
Minitab
Agile
Six Sigma
GD&T
SAP Products
Word/Pages/Docs
SolidWorks
Excel/Numbers/Sheets

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Minimum 8 years related experience in engineering and manufacturing of metal injection molding (MIM), plastic injection molding (PIM), and/or machining. Hands on plastic injection molding experience is highly desirable, including but not limited to Scientific Injection Molding (SIM) principles, plastic DFM, Silicone molding (LSR and/or compression molding).
  • Excellent written and verbal communication skills including presentations to executive level management and technical SMEs within Design Engineering, Manufacturing Engineering, & Supplier Engineering
  • Excellent Interpersonal skills and team building skills. Ability to build and foster great working relationships with external suppliers is invaluable.
  • A proven history of implementing Lean/6 Sigma/SPC Programs at suppliers
  • Excellent Project Management skills
  • Excellent analytical and problem solving skills along with good judgment
  • Demonstrable knowledge in evaluating and challenging supplier technical, quality, and business capabilities
  • Demonstrable knowledge of a wide range of manufacturing processes including understanding of key input variables for quality, cost, and capacity (specialization can be in metal fabrication, plastics, electronics, and/or contract manufacturing)
  • Excellent knowledge of 21 CFR part 820 and ISO 13485
  • Significant computer experience using Windows, Word, Excel, Project, Access, and ERP Information Systems, preferably SAP or Agile
  • CAD experience with 3D modeling tools is a plus, such as SolidWorks
  • Experience with statistical analysis software such as Minitab is a plus
  • Proven ability to motivate suppliers
  • Experience in a high-volume medical device company is a plus
  • Ability to read and interpret detailed mechanical drawings (GD&T) and communicate technical information
  • Ability to travel to suppliers on an as-needed basis – domestic and international
  • BS degree in Engineering (Mechanical, Industrial, Manufacturing, Biomedical, Polymer Science etc.) or equivalent experience. Advanced degree preferred.
Responsibilities
  • Complete project/ part qualification deliverables including Supplier pFMEA, Process Validations (IQ/OQ/PQ), Inspection Reports, Gage R&R, and Process Capability Analysis
  • Work with suppliers to execute cost reductions, capacity improvements, and supply chain risk mitigation efforts like dual sourcing or supplier driven design improvements.
  • Select the right process and supplier for the part, considering long term fit and total cost of ownership
  • Manage supplier changes including manufacturing process changes, production optimization, facility changes, new equipment qualification, and new line validations
  • Drive changes to ISI requirements as necessary by initiating and managing changes to specifications and drawings through the engineering change order process
  • Own and drive to closure supplier variances from symptom through root cause analysis to corrective action, including careful CAPA documentation
  • Effectively prioritize and advance multiple concurrent projects and tasks
  • Clearly communicate project status to key stakeholders
  • Build, own, and relentlessly pursue a vision for developing suppliers
  • Understand proper level of documentation detail for tracking of actions and justification of decisions
  • Generate key metrics for the team and suppliers, and continually drive for timely achievement of those metrics
  • Drive suppliers to continually improve their business and manufacturing process performance to meet Intuitive’s requirements for supplier excellence using a collection of best practices in project management, Six Sigma, Lean, SPC and negotiation. Lead these efforts without managerial guidance at several suppliers simultaneously
  • Implement corrective and preventive actions for supplier process by driving supplier’s investigations and root cause analysis, reduce issue recurrence through thorough RCA implementation.
  • DFM by engaging suppliers early in development cycle to feedback manufacturability improvements in the designs prior to production
  • Influence and guide Engineering in choosing suppliers by determining selection criteria for preferred suppliers and leading the team effort to evaluate & build preferred suppliers
  • Review, analyze and close customer complaints, manufacturing variance requests, and first article inspections by judging risk analyses and justifications
  • Work with suppliers and ISI engineering for the new product introduction to:
  • Create product supplier landscapes to determine launch readiness and report to management
  • Develop supplier ramp readiness plans by judging business risk based on forecast, supplier capacity, quality performance, and process capability.
  • Collaborate with Supply Chain & purchasing organizations to ensure new suppliers meet financial and viability thresholds to onboard onto Intuitive Approved Supplier List.
Desired Qualifications
  • New product development experience is a plus

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates again.
  • Intuitive raised 2026 da Vinci procedure growth guidance to 13.5%-15.5%.
  • Asia-Pacific demand supports Penang operations starting 2028 and 1,200 jobs by 2032.

What critics are saying

  • FDA Class II recalls in 2026 hit da Vinci X, Xi, and SP components.
  • US da Vinci growth slowed to 12% in Q2 2026, signaling elective-procedure deferral.
  • Medtronic's Hugo and other robotic entrants erode Intuitive's pricing power by 2027.

What makes Intuitive Surgical unique

  • Da Vinci 5 deepens Intuitive Surgical's installed-base moat; Q2 2026 placements hit 468.
  • Recurring instruments and accessories drove 85% of Q2 2026 revenue, stabilizing cash generation.
  • Penang facility in Malaysia expands manufacturing resilience for da Vinci instruments and electromechanical devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.